Beckman Coulter Diagnostics announced Kevin O’Reilly’s appointment as its new president succeeding Julie Sawyer Montgomery, who is now vice president and group executive, Danaher Diagnostics.
“Kevin brings more than 30 years of leadership experience, including accelerating and delivering innovation on a global scale within the healthcare industry,” says Sawyer Montgomery. “He is passionate about developing talent and winning teams to serve customers and meet patient needs through innovation and operational excellence. Kevin’s experience running a complex operating division as president, coupled with his track record of achieving results equips him well to lead Beckman Coulter Diagnostics’ next chapter.”
Most recently, O’Reilly served as president of Radiation Oncology Solutions at Varian Medical Systems, where he was responsible for more than $3 billion in revenue and 6,500 associates worldwide, the company says. Throughout his nearly 15-year tenure with Varian, he led end-to-end solutions for all radiation therapy customers, including R&D and product strategy, supply chain and manufacturing, and all global sales, service, and marketing. Under O’Reilly’s leadership, Varian achieved record revenue, world-class customer satisfaction, and industry-leading associate engagement scores across all regions while growing market share.
“Every hour around the world, more than a million clinical samples – representing up to a million people – are analyzed using Beckman Coulter Diagnostics platforms,” says O’Reilly. “I am very excited to join this team with its legacy of innovation and its deep pipeline of diagnostics advancements designed to play a vital role in improving healthcare outcomes worldwide.”
Kevin holds an Honors diploma from the Technical University of Ireland and Bachelor of Science in Electrical Engineering from Trinity College.
Further reading: Beckman Coulter Unveils New Clinical Chemistry Analyzer
Featured image: Kevin O’Reilly. Photo: Beckman Coulter